Amarin Q2 2016 Earnings and Investor Conference Call

Amarin Corporation presented second quarter 2016 financial and operational results with raised full-year net product revenue guidance of $112-125 million. The presentation highlights the commercial performance of Vascepa® and updates on the company's product development and regulatory efforts. Intended for investor communication only.